# Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain

> **NCT02447848** · PHASE3 · COMPLETED · sponsor: **Talphera, Inc** · enrollment: 76 (actual)

## Conditions studied

- Moderate-to-severe Acute Pain

## Interventions

- **DRUG:** sufentanil sublingual 30 mcg tablet

## Key facts

- **NCT ID:** NCT02447848
- **Lead sponsor:** Talphera, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2016-06
- **Final completion:** 2016-07
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2017-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02447848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02447848, "Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02447848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*